LumellaPOC | Preeclampsia and Gestational Diabetes Point-of-Care Test
20631
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-20631,ajax_fade,page_not_loaded,,select-theme-ver-2.4,wpb-js-composer js-comp-ver-4.6.2,vc_responsive

The Lumella test, the new point-of-care blood test helps in early detection of Preeclampsia

The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia.

 

The Lumella test requires a simple finger stick and can be performed in physician’s office/clinic in the first, second, or third trimesters, between 13 to 37 weeks of gestation.

 

Lumella Documents

 

Lumella Product Information Sheet CE

 

Lumella Quick Reference Guide

 

Quick Reference Guide Addendum

 

Lumella Reader User Guide

 

Lumella Patient Education:
Brochure 1 | Brochure 2 | Brochure 3

 

Diabetomics, Inc. is a global medical diagnostics company pioneering innovative, non-invasive point-of-care tests that are especially useful in alleviating the substantial economic and public health burden of maternal health and diabetes in low and middle income countries.

ADDRESS

Diabetomics, Inc.
2345 NE Overlook Dr.
Suite #140
Hillsboro, OR 97006

PHONE

503-924-5110
Toll-Free 877-748-9355

FAX

503-924-5111

CONTACT US

 

Contact Us
First
Last
I am a *